Karyopharm Therapeutics Inc (KPTI) Upgraded to “Hold” by Zacks Investment Research

Karyopharm Therapeutics Inc (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Other analysts have also issued reports about the stock. Jefferies Group LLC reiterated a “buy” rating and set a $14.00 target price (up from $12.00) on shares of Karyopharm Therapeutics in a research report on Sunday, December 4th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 target price on shares of Karyopharm Therapeutics in a research report on Monday, March 13th. HC Wainwright restated a “buy” rating and issued a $14.00 price target (down from $15.00) on shares of Karyopharm Therapeutics in a research report on Tuesday, March 7th. Finally, Wedbush restated an “outperform” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, March 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $13.76.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.67 on Tuesday. The firm’s market cap is $440.06 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The company’s 50 day moving average is $10.71 and its 200-day moving average is $9.69.

Your IP Address:

A number of institutional investors have recently added to or reduced their stakes in KPTI. Palo Alto Investors LLC raised its position in Karyopharm Therapeutics by 3.7% in the fourth quarter. Palo Alto Investors LLC now owns 3,200,396 shares of the company’s stock worth $30,084,000 after buying an additional 114,547 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the period. Trexquant Investment LP purchased a new position in Karyopharm Therapeutics during the fourth quarter worth approximately $273,000. Dimensional Fund Advisors LP raised its position in Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock worth $2,454,000 after buying an additional 202,714 shares during the period. Finally, State Street Corp raised its position in Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock worth $3,820,000 after buying an additional 25,015 shares during the period. Hedge funds and other institutional investors own 56.97% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.